Demonstrating a significant innovation over fed-batch and semi-continuous manufacturing processes
We are a global Continuously Innovative Development and Manufacturing Organization (CIDMO), dedicated to changing the paradigm by which affordable biologic and biosimilar medicines are brought to market. Since Enzene’s inception, our innovative agility has enabled us to continually introduce transformative processes in biologics manufacturing that significantly increase product yields of complex biologics and monoclonal antibodies (mAbs) while reducing the manufacturing footprint and the cost of production.
Game-changing innovation is only the beginning, though. We are Enzene, and that means that our values of innovation, entrepreneurship, respect, candor, excellence, and integrity underscore everything we do from project management and communications to teamwork and ideation. To us, true partnership is about driving biotech innovation while doing so in a way that develops long-lasting trusted partnerships.
We are a global Continuously Innovative Development and Manufacturing Organization (CIDMO), dedicated to changing the paradigm by which affordable biologic and biosimilar medicines are brought to market. Since Enzene’s inception, our innovative agility has enabled us to continually introduce transformative processes in biologics manufacturing that significantly increase product yields of complex biologics and monoclonal antibodies (mAbs) while reducing the manufacturing footprint and the cost of production.
Game-changing innovation is only the beginning, though. We are Enzene, and that means that our values of innovation, entrepreneurship, respect, candor, excellence, and integrity underscore everything we do from project management and communications to teamwork and ideation. To us, true partnership is about driving biotech innovation while doing so in a way that develops long-lasting trusted partnerships.
EnzeneX™ minimizes product contact with cell culture fluid, ensuring high-quality manufacturing. This is crucial for biologics that are prone to degradation including less stable and difficult-to-express proteins.
EnzeneX™ reduces processing costs by approximately 50%, providing you with cost-effective manufacturing. This is achieved with a lower cost of goods and efficient use of resources.
EnzeneX™ provides flexibility with a minimum 30-50L supply.
The modular and variable bioreactors enable scale-on and scale-out flexibility, allowing you to adapt to changing production needs and optimize your manufacturing capacity.
EnzeneX™ increases your manufacturing productivity, achieving approximately 10 times higher productivity than traditional fed-batch manufacturing
EnzeneX™ increases sustainability by reducing the equipment footprint and carbon footprint of manufacturing processes.
Discover the science behind our patented and fully validated fully-connected continuous manufacturing™.
EnzeneX™ has enabled us to successfully manufacture commercial monoclonal antibodies (mAbs) and convert biologics from fed-batch production to FCCM™.
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.